S 1041: Affordable Prescriptions for Patients Act

S 1041 in plain English: This bill limits the number of patents that a brand-name biologic drug manufacturer can use in a patent infringement lawsuit against a company trying to sell a cheaper biosimilar version. The restrictions apply when the biosimilar manufacturer follows certain information-sharing steps under the existing FDA approval framework. Courts may allow exceptions to the limit when justice or good cause requires it.

Stated purpose

This bill aims to make biosimilar drugs more affordable and accessible by limiting the number of patents a brand-name biologic drug maker can use to block or delay a biosimilar competitor in court.

Key points

• Limits the number of patents a brand-name biologic maker can assert in lawsuits against biosimilar competitors
• Restricts use of patents filed more than four years after the original biologic drug received market approval
• Biosimilar makers must complete certain information-sharing steps to qualify for the patent limits
• Excludes patents covering specific methods of using the biologic drug from the limitations
• Courts may raise the patent limit if there is good cause or justice requires it

Arguments supporters make

• Brand-name drug companies sometimes file large numbers of patents years after a drug is approved just to block competition, and capping those patents gives biosimilar makers a fair shot at entering the market.
• More biosimilars on the market creates competition that can lower prices, making life-saving biologic drugs more affordable for patients.
• The bill still allows courts to raise the patent limit when there is a genuine legal reason, so legitimate patent rights are not simply thrown away.

Arguments opponents make

• Limiting how many patents a company can assert may prevent it from fully defending real innovations, potentially weakening incentives to invest in developing complex and costly biologic drugs in the future.
• Patent filings after initial approval can reflect genuine improvements or new manufacturing discoveries, and a strict cap based on filing date does not distinguish frivolous patents from truly important ones.
• The cap only applies if the biosimilar applicant completes certain steps, but those conditions are complex, and the rules could create new legal disputes over whether the limit applies rather than simplifying litigation.

Tradeoffs

Restricting patent assertions may speed up competition and lower drug prices for patients, but could reduce the legal protections that encourage the costly research needed to develop new biologic medicines in the first place.

Current status in Congress: In committee.

NewsClear — neutral news & congressional tracking · Bill of the Week